67 results
8-K
EX-99.1
REVB
Revelation Biosciences Inc
22 Mar 24
Results of Operations and Financial Condition
4:22pm
or slow the progression of chronic kidney disease (GEMINI-CKD program). Revelation believes Gemini works through trained immunity, which redirects
8-K
EX-99.1
REVB
Revelation Biosciences Inc
8 Feb 24
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
4:01pm
for acute kidney injury, and GEMINI-CKD for the treatment of chronic kidney disease.
For more information on Revelation, please visit
8-K
EX-99.2
z0p8wdwnperkyxmv
8 Feb 24
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
4:01pm
424B3
6ltm3om
2 Feb 24
Prospectus supplement
4:06pm
8-K
EX-99.1
fkeo1 h2j
30 Jan 24
Developing innovative therapeutics to address unmet needs Corporate Presentation / January 2024 www.revbiosciences.com
5:21pm
8-K
EX-99.1
il5m jdwe239
13 Nov 23
Results of Operations and Financial Condition
4:30pm
8-K
EX-99.2
5b07erfo9dknfcdt
12 Oct 23
Developing innovative therapeutics to address unmet needs Corporate Presentation / October 2023 www.revbiosciences.com
4:26pm
8-K
EX-99.1
xyl97eqq
12 Oct 23
Developing innovative therapeutics to address unmet needs Corporate Presentation / October 2023 www.revbiosciences.com
4:26pm
8-K
EX-99.1
tlmnkc8ik wpr4wzyr
2 Oct 23
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
4:24pm
8-K
EX-99.1
nt96i3
11 Aug 23
Results of Operations and Financial Condition
4:30pm
8-K
EX-99.1
dcqyh
29 Jun 23
Regulation FD Disclosure
4:23pm
8-K
EX-99.1
ljtemnhnw6
12 Jun 23
Regulation FD Disclosure
4:20pm